Global Hormone Replacement Therapy (HRT) Market to Reach US$3.04 Billion by 2017, According to a New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on Hormone Replacement Therapy (HRT) markets. The global market for Hormone Replacement Therapy (HRT) is forecast to reach US$3.04 billion by the year 2017. The global market for HRT for treating menopausal symptoms represents tremendous growth potential given the lack of safer alternatives, and the huge existing and anticipated demand owing to the number of women transitioning through menopause. Although the employment of HRT for menopausal symptom relief is facing pressure, the lack of available alternatives is expected to protect its usage for a long time.

Hormone Replacement Therapy (HRT): A Global Strategic Business Report

Follow us on LinkedIn - Women going through menopause may experience a broad range of symptoms, including night sweats and hot flashes, and these symptoms affect nearly 75% of women aged more than 50 years. Irrespective of the large number of women that experience menopausal symptoms, a major percentage of these women still do not seek treatment. Only 60% of the symptomatic women in the US typically consult a healthcare provider.

Hormone therapy has been the treatment of choice for relief from menopausal symptoms since the 1960s, and proved to be a huge success with prescriptions going up to several millions in the US. However, studies taken up to rule out any confusion with regards to the role of hormone therapies in increasing disease risks brought to light serious safety issues that in turn brought the market to a standstill and led to a drastic decline thereafter. In addition, the widespread media coverage of the study outcomes raised doubts among physicians and women on the safety of hormone therapies. Moreover, the lack of other available alternatives, such as non-hormonal drugs has created a huge need for effective options to address the needs of women experiencing post-menopausal symptoms. Although a number of safer off-label drugs are available, their efficacy is not at par with hormone therapies, and the market remains highly under-served.

Development of low-dose oral alternatives is likely to stabilize the drastic decline in the market that began in 2003 as the oral HRT segment represents the worst hit of all. There is scope for further improvement in the efficacy of these drugs/products and also making them much safer that would drive the market stabilization. Further, novel product releases, specifically transdermal patches, gels, and creams, is expected to promote market growth in the foreseeable future, albeit at a slower pace and to a lesser extent.

The US holds a lion’s share of the global market for Hormone Replacement Therapy, as stated by the new market research report on Hormone Replacement Therapy. Europe represents a distant second, while growth is expected to emanate mainly from the Asia-pacific region, which is forecasted to emerge as the fastest growing market for HRT, with a CAGR of more than 3.0% over the analysis period.

The market for Hormone Replacement Therapy witnessed a major blow in 2002 with the findings of the Women’s Health Initiative and other similar studies thereafter that profoundly affected the number of women willing to take up HRT, and prescribing physicians as well. The reason being systemic absorption of HRT drugs resulting in increased risk of breast cancer, stroke and cardiovascular diseases that outweighed the benefit of lowered risk of hip fracture due to osteoporosis. Systemic absorption is the case with oral HRTs, while transdermal HRTs (patches, gels, creams) although do not assure strictly local absorption, are considered comparatively safer to oral drugs. Development of low-dose oral drugs and locally acting transdermal HRT products with high efficacy has captured the attention of players in the HRT market.

Major players profiled in the report include Bayer HealthCare Pharmaceuticals Inc., Besins Healthcare SA, Hisamitsu Pharmaceutical Co. Inc., Noven Pharmaceuticals Inc., Mylan, Novartis AG, Novo Nordisk A/S, Orion Corp., Pfizer Inc., among others.

The report titled “Hormone Replacement Therapy (HRT): A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of Hormone Replacement Therapy (HRT) for treatment of menopausal symptoms, the approved therapies, pipeline analysis, the industry overview, market trends, product overview, recent industry activity, FDA approvals, recent launches, and profiles of major/niche global market participants. The report provides annual value sales estimates and projections for Hormone Replacement Therapy market for the years 2009 through 2017 for the following geographic regions – US, Canada, Europe, Asia-Pacific, and Rest of World. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.

For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Hormone_Replacement_Therapy_HRT_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn.

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website

Media